Are Sanofi India latest results good or bad?

Sanofi India has reported its financial results for the quarter ending March 2025, showcasing notable operational trends. The company achieved a Profit Before Tax (PBT) of Rs 162.00 crore, reflecting a significant growth compared to the average PBT of Rs 88.25 crore over the previous four quarters. This suggests a strong near-term outlook for profitability.
In terms of cash flow, Sanofi India recorded its highest operating cash flow in three years at Rs 461.70 crore, indicating robust cash revenues from business operations. Additionally, net sales reached Rs 535.90 crore, marking a five-quarter high, while the operating profit (PBDIT) stood at Rs 171.90 crore, with an operating profit margin of 32.08%, which points to improved operational efficiency.

However, the company is facing challenges, notably a declining Debtors Turnover Ratio, which fell to 8.75 times, indicating a slower pace in settling debts. Furthermore, the annual dividend per share has decreased to Rs 117.00, the lowest in five years, suggesting a reduction in shareholder returns.

Overall, the financial results indicate a mixed operational landscape for Sanofi India, with the company experiencing both positive growth in key metrics and certain challenges that may impact its financial health. Additionally, the company saw an adjustment in its evaluation based on these results.